预存在的共病症在癌症治疗选择中起着重要作用。我们对一组患有I-III期乳腺癌的黑人女性的预现有的共病症与局部和全身治疗接受之间的关系进行了回顾性评估。分析的研究人群包括1169名患有I-III期疾病的女性，她们参加了底特律癌症幸存者研究（ROCS）队列的登记。共病症、社会人口学和临床变量的信息是通过自填问卷和癌症登记获取的。共病症分别进行了单独分析，并将共病负担分为低（0-1）、中等（2-3）和高（≥4）三个类别。我们使用逻辑回归分析评估了与局部治疗（手术±放射治疗；N = 1156）、激素治疗（N = 848）和化疗（N = 680）接受相关的因素。调整后的模型包括在单变量分析中显著预测因素的先验选择变量。治疗接受程度被分为局部治疗（82.6%）、激素治疗（73.7%）和化疗（79.9%）。关节炎和抑郁症的既往病史与接受局部治疗的可能性较小相关，[比值比（OR），95%置信区间（CI），0.66，0.47-0.93和0.53，0.36-0.78]。肥胖与接受激素治疗的可能性较大相关（OR: 1.64，95% CI: 1.19，2.26），心力衰竭与接受激素治疗的可能性较小相关（OR: 0.46，95% CI: 0.23，0.90）。年龄较大（趋势P < 0.01）和共病负担增加（趋势P = 0.02）与接受化疗的可能性较小相关。既往患有的共病症对于接受推荐的针对癌症的治疗可能具有不利影响，这包括了I-III期乳腺癌女性患者。© 2023 The Authors. 《癌症医学》由约翰威利和子公司出版。

Pre-existing comorbidities play an important role in choice of cancer treatment. We retrospectively evaluated the relationship between pre-existing comorbidities and receipt of local and systemic therapy in a cohort of Black women with Stage I-III breast cancer.The study population for analysis included 1169 women with Stage I-III disease enrolled in the Detroit Research on Cancer Survivors (ROCS) cohort. Information on comorbidities, socio-demographic, and clinical variables were obtained from self-reported questionnaires and the cancer registry. Comorbidities were analyzed individually, and comorbidity burden was categorized as low (0-1), moderate (2-3) or high (≥4). We used logistic regression analysis to evaluate factors associated with receipt of local treatment (surgery ± radiation; N = 1156), hormonal (N = 848), and chemotherapy (N = 680). Adjusted models included variables selected a priori that were significant predictors in univariate analysis.Receipt of treatment was categorized into local (82.6%), hormonal (73.7%), and/or chemotherapy (79.9%). Prior history of arthritis and depression were both associated with a lower likelihood to receive local treatment, [odds ratio (OR), 95% confidence interval (CI), 0.66, 0.47-0.93, and 0.53, 0.36-0.78], respectively. Obesity was associated with higher likelihood of receiving hormonal therapy (OR: 1.64, 95% CI: 1.19, 2.26), and heart failure a lower likelihood (OR: 0.46, 95% CI: 0.23, 0.90). Older age (Ptrend  <0.01) and increasing co-morbidity burden (Ptrend  = 0.02) were associated with lower likelihood of receiving chemotherapy.History of prior co-morbidities has a potentially detrimental influence on receipt of recommended cancer-directed treatment among women with Stage I-III breast cancer.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.